Ascendis Pharma A (ASND) Interest Expenses (2013 - 2026)

Ascendis Pharma A (ASND) has 14 years of Interest Expenses data on file, last reported at $78.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 67.14% year-over-year to $78.7 million; the trailing twelve-month figure through Mar 2026 stood at $446.9 million (up 1006.5% YoY), and the FY2025 full-year result was $240.6 million, up 122.23% from the prior year.
• Interest Expenses slipped to $78.7 million in Q1 2026, from $409.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $409.0 million in Q4 2025 to a low of -$78.2 million in Q3 2025.
• A 5-year average of $40.3 million and a median of $10.6 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses plunged 204.29% in 2024 and soared 2944568.45% in 2025, its largest moves.
• Tracing ASND's Interest Expenses over 5 years: stood at -$314236.2 in 2022, then soared by 2984.71% to $9.1 million in 2023, then sank by 100.15% to -$13891.7 in 2024, then soared by 2944568.45% to $409.0 million in 2025, then sank by 80.75% to $78.7 million in 2026.
• Business Quant data shows ASND's Interest Expenses at $78.7 million in Q1 2026, $409.0 million in Q4 2025, and -$78.2 million in Q3 2025.